Utility of subjective-effects measurements in assessing abuse liability of drugs in humans.
about
Amphetamine-induced place preference in humansPositron emission tomography molecular imaging of dopaminergic system in drug addictionDo initial responses to drugs predict future use or abuse?MDMA: a social drug in a social context.Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trialAmphetamine fails to alter cued recollection of emotional images: study of encoding, retrieval, and state-dependencyEffects of acute methamphetamine on emotional memory formation in humans: encoding vs consolidationThe implications of methylphenidate use by healthy medical students and doctors in South Africa.A window into the intoxicated mind? Speech as an index of psychoactive drug effectsTopiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking.In the company of others: social factors alter acute alcohol effectsRelationship between oral D-amphetamine self-administration and ratings of subjective effects: do subjective-effects ratings correspond with a progressive-ratio measure of drug-taking behavior?The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for painEffects of MDMA and Intranasal oxytocin on social and emotional processing.Exposure-Response Relationships during Free-Access Intravenous Alcohol Self-Administration in Nondependent Drinkers: Influence of Alcohol Expectancies and Impulsivity.Relationship between drug discrimination and ratings of subjective effects: implications for assessing and understanding the abuse potential of D-amphetamine in humans.Effects of the nicotinic acetylcholine receptor antagonist mecamylamine on the discriminative stimulus effects of cocaine in male rhesus monkeys.Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humansHuman behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.Effects of delta 9-THC on marijuana smoking, dose choice, and verbal report of drug liking.The drug effects questionnaire: psychometric support across three drug typesCaffeine increases striatal dopamine D2/D3 receptor availability in the human brain.Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers.Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability.Personality and the acute subjective effects of d-amphetamine in humans.Psychoactive drugs and false memory: comparison of dextroamphetamine and δ-9-tetrahydrocannabinol on false recognition.Amphetamine increases errors during episodic memory retrievalStress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkersDifferent lengths of times for progressions in adolescent substance involvement.Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humansPerformance and subjective effects of diazepam and d-amphetamine in high and low sensation seekers.Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteersClinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.Dopamine in drug abuse and addiction: results from imaging studies and treatment implications.Effects of amphetamine on reactivity to emotional stimuli.Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotineCardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.Effects of buprenorphine on responses to social stimuli in healthy adults.
P2860
Q22252505-A3D130D3-D82A-4A29-902A-5C1093C91C86Q26992051-513DE01D-5B5F-4292-B6D5-BB5286B64056Q27025975-1D65F112-1C0B-48DC-B24E-F6EC58E59639Q27325091-5363C2C9-CFA2-4EDB-9AB1-901605869A63Q28480500-046F0202-65C6-49EF-B428-07B122435412Q28540215-0CDC7E60-24C4-459B-A292-7812709DE2BDQ28543452-768BC085-EE2B-443E-BECA-92EBF114F338Q30359758-6D80423A-C181-4FAA-ABE3-6211723F66A4Q30404060-FC97AE83-3DD8-4C02-8002-F95D5512B213Q30413247-A3A9CC1E-89CD-4411-A515-1315493B0F94Q30552032-58A72B85-E394-4589-B74D-4F124B748B2AQ33574891-47448671-8FF2-4C2F-804D-31509CE46834Q33578856-0F24BF23-3764-465D-B21B-E8055CB19AB9Q33620569-65F32971-390F-4511-AAA9-86ECEB5F9D3AQ33625361-772B68C4-D23D-4059-A5EC-29A2734BEC24Q33757297-B1347D1D-9DC8-41ED-8B11-CEBF74473A72Q33794070-33EA4DF0-5F04-4BAB-A6B7-E7061D97B3ADQ33870495-88D84DC7-D54C-409B-BF9D-35EBF43D252BQ34033200-A0127F1D-DD52-4BFD-980F-70E3D4E7D887Q34270067-FC086E88-82C3-4DE8-BF17-8131DDADAD54Q34319831-809F9F24-E0B9-4414-888B-E7FFA072BD06Q34471546-5C2F2865-1961-40B7-AE79-B1583B2D3FF6Q34477182-2FE4EFAA-7BAD-4582-AD6A-22163B1A841AQ34533895-1AC402A0-AB24-4213-AB47-5A78ADCCE912Q34536352-828E106D-2C3F-4620-87DE-3C393F114AA7Q34560588-69933BF8-47F6-4561-AAEC-999931836C86Q34575176-43DD17BB-8C18-4109-ADBB-DBEAAFC666BFQ34575194-04ABC3EA-73AD-4847-9908-A2559773845AQ34661786-B6A0BF95-7AD6-4971-B25B-15CBB8F449C9Q34928953-507006C2-87AF-4650-9149-6DEF045D97E0Q34979634-72C290B8-A337-494A-8A84-234D1F53A83EQ35141064-E9266F92-B10C-4BB3-BE17-5F527DE5FE1CQ35576598-7F28CA45-1A8B-4130-8337-E1ED048A5433Q35580343-D23BB429-D64D-4988-A80B-B6CC0260AE94Q35684589-25B61EDF-CC24-433C-BDD0-78702D442786Q35751195-361B6D5B-DCC9-4638-91D9-7B7656465C4CQ35751414-71440AC0-8F36-4B6D-8461-BC167F1B3229Q35892758-9FCF741E-2176-49C7-A378-B8F9082AD09BQ36165527-8FED11F1-F76F-4E61-8776-22C747CAAE77Q36414570-3BEE2546-FFA2-47EA-8DBF-1803701A03CB
P2860
Utility of subjective-effects measurements in assessing abuse liability of drugs in humans.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Utility of subjective-effects ...... liability of drugs in humans.
@en
type
label
Utility of subjective-effects ...... liability of drugs in humans.
@en
prefLabel
Utility of subjective-effects ...... liability of drugs in humans.
@en
P1476
Utility of subjective-effects ...... liability of drugs in humans.
@en
P2093
Fischman MW
P304
P356
10.1111/J.1360-0443.1991.TB01749.X
P577
1991-12-01T00:00:00Z